Capital Markets & Financing

Cullgen Raises $40 Million in New Financing Led by AstraZeneca-CICC Fund

SAN DIEGO & SHANGHAI--(BUSINESS WIRE)-- Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that it has raised $40 million in new financing.